Compare Enphase Energy Inc (ENPH) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enphase Energy Inc vs Novo Nordisk A/S — how do they compare? Enphase Energy Inc trades at $42.6 (market cap $5.81B), while Novo Nordisk A/S trades at $51.5 (market cap $222.24B). The key difference: Novo Nordisk A/S is far larger — about 38.3× Enphase Energy Inc's market cap, and Novo Nordisk A/S pays a 3.56% dividend while Enphase Energy Inc pays none. Which is the better fit depends on your goals.
| ENPH | NVO | |
|---|---|---|
Market Cap | $5.81B | $222.24B |
Sector | Technology | Health |
52-Week High | $72.33 | $71.70 |
52-Week Low | $26.12 | $35.29 |
Enterprise Value | $5.46B | $241.20B |
Dividend Yield | — | 3.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Enphase Energy (ENPH) trades at $44.985, up 4.47% with a neutral technical signal despite bullish moving averages. The company has beaten earnings expectations for three consecutive quarters, though revenue declined from $2.3B in 2023 to $1.47B in 2025. Analyst sentiment is mixed with 40% buy ratings but a consensus price target of $42.79 below current levels. Recent news highlights product expansions in Europe and Australia alongside ongoing legal scrutiny.
ENPH faces near-term headwinds with declining revenue and compressed margins, but maintains strong profitability metrics and consistent earnings beats. Investment appeal hinges on international growth execution and potential regulatory tailwinds, balanced against competitive pressures and stock volatility. The current valuation at 43.61 P/E requires robust growth reinstatement to justify upside.
Novo Nordisk (NVO) trades at $49.07, down 0.43% on the day, amid a bullish technical signal and strong fundamental performance. The stock exhibits robust profitability with a 37.2% net income margin and has beaten earnings estimates for three consecutive quarters. Recent news highlights EU approval for its Wegovy weight-loss pill, reinforcing its competitive position in the GLP-1 market.
The outlook remains positive given earnings momentum and expanding product approvals, though risks include rising competition from generics and potential prescription slowdowns. Analyst consensus is bullish with 57.9% buy ratings, supporting a favorable risk-reward profile for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enphase Energy Inc
Enphase Energy is a global energy technology company. The company delivers smart, easy-to-use solutions that manage solar generation, storage, and communication on one platform. The company's microinverter technology primarily serves the rooftop solar market and produces a fully integrated solar-plus-storage solution. Geographically, it derives a majority of revenue from the United States.
Read more on ENPH →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
